In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sellas Life Sciences Group Inc.

www.sellaslifesciences.com

Latest From Sellas Life Sciences Group Inc.

Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology

RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.

Business Strategies Platform Technologies

Amphera Gears Up To Evaluate Dendritic Cells For Pleural Mesothelioma

Dutch biotech Amphera has progressed into late-stage clinical studies with dendritic cells activated with an allogeneic lysate of tumor cell lines; the dendritic cells are expected to have a therapeutic effect in patients with mesothelioma, a tumor with few treatment options.

 

Clinical Trials ImmunoOncology

Sellas Will Take Increasingly Good Results With NeuVax Into FDA Discussions

Preparing to meet with FDA in December to plan next steps for NeuVax in triple-negative breast cancer, Sellas reveals 26-month data that show further clinical benefit compared with a 19-month interim look. Firm still hopes to out-license the vaccine candidate.

Regulation Drug Approval Standards

Pipeline Watch: Phase III Starts With Enzastaurin, Sparsentan And Abaloparatide

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • RXi Pharmaceuticals Corp.
  • Galena Biopharma Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sellas Life Sciences Group Inc.
  • Senior Management
  • Angelos M Stergiou, MD, Pres. & CEO
    Nicholas J Sarlis, MD, PhD, CMO
    John Burns, VP, Fin.
  • Contact Info
  • Sellas Life Sciences Group Inc.
    Phone: (917) 438-4353
    15 W. 38th St.
    10th Fl.
    New York, NY 10018
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register